Kyorin Pharma To Shut Down US Subsidiary ActivX
End Of Line For 2004 Acquisition
Kyorin Pharma is to end operations at its US subsidiary ActivX 18 years since its acquisition. Although the California firm’s kinase-probing technology has contributed to Kyorin’s R&D, the Japanese firm acknowledged limits to future applicability in the development of candidate compounds.
